Prudential Financial Inc. grew its position in LivaNova PLC (NASDAQ:LIVN) by 100.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 95,560 shares of the company’s stock after buying an additional 47,975 shares during the quarter. Prudential Financial Inc. owned 0.20% of LivaNova worth $11,847,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Schwab Charles Investment Management Inc. grew its holdings in shares of LivaNova by 4.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 286,372 shares of the company’s stock valued at $28,586,000 after purchasing an additional 12,517 shares during the last quarter. BlackRock Inc. grew its holdings in shares of LivaNova by 6.1% during the 2nd quarter. BlackRock Inc. now owns 5,393,015 shares of the company’s stock valued at $538,332,000 after purchasing an additional 309,138 shares during the last quarter. Cibc Bank USA bought a new stake in shares of LivaNova during the 3rd quarter valued at approximately $227,000. State Treasurer State of Michigan grew its holdings in shares of LivaNova by 11.8% during the 3rd quarter. State Treasurer State of Michigan now owns 18,000 shares of the company’s stock valued at $2,231,000 after purchasing an additional 1,900 shares during the last quarter. Finally, Dupont Capital Management Corp bought a new stake in shares of LivaNova during the 3rd quarter valued at approximately $719,000. 87.53% of the stock is currently owned by institutional investors.
In other LivaNova news, insider David S. Wise sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $112.83, for a total transaction of $169,245.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $116.68, for a total transaction of $116,680.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,500 shares of company stock worth $1,002,355 over the last three months. Insiders own 0.41% of the company’s stock.
LIVN opened at $101.19 on Monday. LivaNova PLC has a fifty-two week low of $76.14 and a fifty-two week high of $131.54. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.21 and a current ratio of 1.65. The company has a market cap of $4.93 billion, a price-to-earnings ratio of 30.57, a price-to-earnings-growth ratio of 3.16 and a beta of 0.86.
LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, October 31st. The company reported $0.82 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.08). LivaNova had a positive return on equity of 8.77% and a negative net margin of 8.31%. The business had revenue of $272.10 million for the quarter, compared to the consensus estimate of $275.03 million. During the same period in the previous year, the firm earned $0.83 earnings per share. The company’s revenue was up 8.3% compared to the same quarter last year. Equities research analysts forecast that LivaNova PLC will post 3.1 EPS for the current fiscal year.
LIVN has been the topic of several research reports. BidaskClub lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 18th. Zacks Investment Research lowered shares of LivaNova from a “buy” rating to a “hold” rating in a report on Thursday, September 20th. Jefferies Financial Group lifted their price target on shares of LivaNova to $150.00 and gave the company a “buy” rating in a report on Tuesday, October 2nd. BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a report on Wednesday, November 21st. Finally, Stifel Nicolaus lifted their price target on shares of LivaNova from $135.00 to $140.00 and gave the company a “buy” rating in a report on Monday, September 17th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $122.20.
TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/12/03/prudential-financial-inc-has-11-85-million-stake-in-livanova-plc-livn.html.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Recommended Story: Trading Strategy
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.